A new approach for potential drug target discovery through in silico metabolic pathway analysis using Trypanosoma cruzi genome information

Memorias do Instituto Oswaldo Cruz

Volumn 104, Issue 8, 2009, Pages 1100-1110

  Alves Ferreira, Marcelo ^a   Guimarães, Ana Carolina Ramos ^a   Capriles, Priscila Vanessa da Silva Zabala ^b   Dardenne, Laurent E ^b   Degrave, Wim M ^a  

^a INSTITUTO OSWALDO CRUZ   (Brazil)

^b LABORATÓRIO NACIONAL DE COMPUTAÇÃO CIENTÍFICA   (Brazil)

Author keywords

Analogous enzyme; Drug target; Metabolic pathways; Metabolism; Trypanosoma cruzi

Indexed keywords

TRYPANOSOMA CRUZI;

EID: 72449136290     PISSN: 00740276     EISSN: 16788060     Source Type: Journal    
DOI: 10.1590/S0074-02762009000800006     Document Type: Article

References (108)

1. Acosta H, Dubourdieu M, Quinõnes W, Cáceres A, Bringaud F, Concepción JL 2004. Pyruvate phosphate dikinase and pyrophosphate metabolism in the glycosome of Trypanosoma cruzi epimastigotes. Comp Biochem and Physiol B 138: 347-356.
2. Adroher FJ, Osuna A, Lupiáñez JÁ 1990. Differential energetic metabolism during Trypanosoma cruzi differentiation. II. Hexokinase, phosphofructokinase and pyruvate kinase. Mol Cell Biochem 94: 71-82.
3. Affranchino JL, De Tarlovsky MN, Stoppani AO 1985. Respiratory control in mitochondria from Trypanosoma cruzi. Mol Biochem Parasitol 16: 289-298.
4. Atwood JA 3rd, Weatherly DB, Minning TA, Bundy B, Cavola C, Opperdoes FR, Orlando R, Tarleton RL 2005. The Trypanosoma cruzi proteome. Science 309: 473-476.
5. Barrett MP, Tetaud E, Seyfang A, Bringaud F, Baltz T 1998. Trypanosome glucose transporters. Mol Biochem Parasitol 91: 195-205.
6. Beach DH, Goad LJ, Holz GG Jr 1986. Effects of ketoconazole on sterol biosynthesis by Trypanosoma cruzi epimastigotes. Biochem Biophys Res Commun 136: 851-856.
7. Berriman M, Ghedin E, Hertz-Fowler C, Blandin G, Renauld H, Bartholomeu DC, Lennard NJ, Caler E, Hamlin NE, Haas B, Böhme U, Hannick L, Aslett MA, Shallom J, Marcello L, Hou L, Wickstead B, Alsmark UCM, Arrowsmith C, Atkin RJ, Barron AJ, Bringaud F, Brooks K, Carrington M, Cherevach I, Chillingworth T-J, Churcher C, Clark LN, Corton CH, Cronin A, Davies RM, Doggett J, Djikeng A, Feldblyum T, Field MC, Fraser A, Goodhead I, Hance Z, Harper D, Harris BR, Hauser H, Hostetler J, Ivens A, Jagels K, Johnson D, Johnson J, Jones K, Kerhornou AX, Koo H, Larke N, Landfear S, Larkin C, Leech V, Line A, Lord A, MacLeod A, Mooney PJ, Moule S, Martin DMA, Morgan GW, Mungall K, Norbertczak H, Ormond D, Pai G, Peacock CS, Peterson J, Quail MA, Rabbinowitsch E, Rajandream M-A, Reitter C, Salzberg SL, Sanders M, Schobel S, Sharp S, Simmonds M, Simpson AJ, Tallon L, Turner CMR, Tait A, Tivey AR, Van Aken S, Walker D, Wanless D, Wang S, White B, White O, Whitehead S, Woodward J, Wortman J, Adams MD, Embley TM, Gull K, Ullu E, Barry JD, Fairlamb AH, Opperdoes F, Barrell BG, Donelson JE, Hall N, Fraser CM, Melville SE, El-Sayed NM 2005. The genome of the African trypanosome Trypanosoma brucei. Science 309: 416-422.
8. Beswick TC, Willert EK, Phillips MA 2006. Mechanisms of allosteric regulation of Trypanosoma cruzi S-adenosylmethionine decarboxylase. Biochemistry 45: 7797-7807.
9. Bilate AM, Cunha-Neto E 2008. Chagas disease cardiomyopathy: current concepts of an old disease. Rev Inst Med Trop Sao Paulo 50: 67-74.
10. Brak K, Doyle PS, McKerrow JH, Ellman JA 2008. Identification of a new class of nonpeptidic inhibitors of cruzain. J Am Chem Soc 130: 6404-6410.
11. Bringaud F, Baltz T 1993. Differential regulation of two distinct families of glucose transporter genes in Trypanosoma brucei. Mol Cell Biol 13: 1146-1154.
12. Bringaud F, Rivière L, Coustou V 2006. Energy metabolism of trypanosomatids: adaptation to available carbon sources. Mol Biochem Parasitol 149: 1-9.
13. Buhaescu I, Izzedine H 2007. Mevalonate pathway: a review of clinical and therapeutical implications. Clin Biochem 40: 575-584.
14. Cáceres AJ, Portillo R, Acosta H, Rosales D, Quinõnes W, Avilan L, Salazar L, Dubourdieu M, Michels PAM, Concepción JL 2003. Molecular and biochemical characterization of hexokinase from Trypanosoma cruzi. Mol Biochem Parasitol 126: 251-262.
15. Canepa GE, Bouvier LA, Urias U, Miranda MR, Colli W, Alves MJ, Pereira CA 2005. Aspartate transport and metabolism in the protozoan parasite Trypanosoma cruzi. FEMS Microbiol Lett 247: 65-71.
16. Cannata JJ, Cazzulo JJ 1984. The aerobic fermentation of glucose by Trypanosoma cruzi. Comp Biochem Physiol B 79: 297-308.
17. Cavazzuti A, Paglietti G, Hunter WN, Gamarro F, Piras S, Loriga M, Allecca S, Corona P, McLuskey K, Tulloch L, Gibellini F, Ferrari S, Costi MP 2008. Discovery of potente pteridine reductase inhibitors to guide antiparasite drug development. Proc Natl Acad Sci USA 105: 1448-1453.
18. Cazzulo JJ 1994. Intermediate metabolism in Trypanosoma cruzi. J Bioenerg Biomembr 26: 157-165.
19. Cazzulo JJ, Cazzulo Franke MC, Franke de Cazzulo BM 1989. On the regulatory properties of the pyruvate kinase from Trypanosoma cruzi epimastigotes. FEMS Microbiol Lett 50: 259-263.
20. Chambers JW, Fowler ML, Morris MT, Morris JC 2008. The antitrypanosomal agent lonidamine inhibits Trypanosoma brucei hexokinase 1. Mol Biochem Parasitol 158: 202-207.
21. Concepción JL, Adjé CA, Quiñones W, Chevalier N, Dubourdieu M, Michels PA 2001. The expression and intracellular distribution of phosphoglycerate kinase isoenzymes in Trypanosoma cruzi. Mol Biochem Parasitol 118: 111-121.
22. Cordeiro AT, Cáceres AJ, Vertommen D, Concepción JL, Michels PA, Versées W 2007. The crystal structure of Trypanosoma cruzi glucokinase reveals features determining oligomerization and anomer specificity of hexose-phosphorylating enzymes. J Mol Biol 372: 1215-1226.
23. Coura JR, Castro SL 2002. A critical review on Chagas disease chemotherapy. Mem Inst Oswaldo Cruz 97: 3-24.
24. Croft SL, Seifert K, Duchêne M 2003. Antiprotozoal activities of phospholipid analogues. Mol Biochem Parasitol 126: 165-172.
25. de Boiso JF, Stoppani AO 1973. The mechanism of acetate and pyruvate oxidation by Trypanosoma cruzi. J Protozool 20: 673-678.
26. de Souza W 2002. From the cell biology to the development of new chemotherapeutic approaches against trypanosomatids: dreams and reality. Kinetoplastid Biol Dis 1: 3.
27. de Souza W 2005. Microscopy and cytochemistry of the biogenesis of the parasitophorous vacuole. Histochem Cell Biol 123: 1-18.
28. de Souza W, Campanati L, Attias M 2008. Strategies and results of field emission scanning electron microscopy (FE-SEM) in the study of parasitic protozoa. Micron 39: 77-87.
29. Dias JC 2006. Chagas disease: successes and challenges. Cad Saude Publica 22: 2020-2021.
30. Dixon H, Ginger CD, Williamson J 1971. The lipid metabolism of blood and culture forms of Trypanosoma lewisi and Trypanosoma rhodesiense. Comp Biochem Physiol B 39: 247-266.
31. Dixon H, Ginger CD, Williamson J 1972. Trypanosome sterols and their metabolic origins. Comp Biochem Physiol B 41: 1-18.
32. Docampo R, de Boiso JF, Stoppani AO 1978. Tricarboxylic acid cycle operation at the kinetoplast-mitochondrion complex of Trypanosoma cruzi. Biochim Biophys Acta 502: 466-476.
33. Docampo R, de Souza W, Miranda K, Rohloff P, Moreno SN 2005. Acidocalcisomes - conserved from bacteria to man. Nat Rev Microbiol 3: 251-261.
34. Doyle PS, Zhou YM, Engel JC, McKerrow JH 2007. A cysteine protease inhibitor cures Chagas' disease in an immunodeficientmouse model of infection. Antimicrob Agents Chemother 51: 3932-3939.
35. Duschak VG, Cazzulo JJ 1991. Subcellular localization of glutamate dehydrogenases and alanine aminotransferase in epimastigotes of Trypanosoma cruzi. FEMS Microbiol Lett 67: 131-135.
36. El-Sayed NM, Myler PJ, Bartholomeu DC, Nilsson D, Aggarwal G, Tran AN, Ghedin E, Worthey EA, Delcher AL, Blandin G, Westenberger SJ, Caler E, Cerqueira GC, Branche C, Haas B, Anupama A, Arner E, Aslund L, Attipoe P, Bontempi E, Bringaud F, Burton P, Cadag E, Campbell DA, Carrington M, Crabtree J, Darban H, da Silveira JF, de Jong P, Edwards K, Englund PT, Fazelina G, Feldblyum T, Ferella M, Frasch AC, Gull K, Horn D, Hou L, Huang Y, Kindlund E, Klingbeil M, Kluge S, Koo H, Lacerda D, Levin MJ, Lorenzi H, Louie T, Machado CR, McCulloch R, McKenna A, Mizuno Y, Mottram JC, Nelson S, Ochaya S, Osoegawa K, Pai G, Parsons M, Pentony M, Pettersson U, Pop M, Ramirez JL, Rinta J, Robertson L, Salzberg SL, Sanchez DO, Seyler A, Sharma R, Shetty J, Simpson AJ, Sisk E, Tammi MT, Tarleton R, Teixeira S, Van Aken S, Vogt C, Ward PN, Wickstead B, Wortman J, White O, Fraser CM, Stuart KD, Andersson B 2005. The genome sequence of Trypanosoma cruzi, etiologic agent of Chagas disease. Science 309: 409-415.
37. Espinosa A, Clark D, Stanley SL Jr 2004. Entamoeba histolytica alcohol dehydrogenase 2 (EhADH2) as a target for anti-amoebic agents. J Antimicrob Chemother 54: 56-59.
38. Freitas RF, Prokopczyk IM, Zottis A, Oliva G, Andricopulo AD, Trevisan MT, Vilegas W, Silva MG, Montanari CA 2009. Discovery of novel Trypanosoma cruzi glyceraldehyde-3-phosphate dehydrogenase inhibitors. Bioorg Med Chem 17: 2476-2482.
39. Fricker SP, Mosi RM, Cameron BR, Baird I, Zhu Y, Anastassov V, Cox J, Doyle PS, Hansell E, Lau G, Langille J, Olsen M, Qin L, Skerlj R, Wong RS, Santucci Z, McKerrow JH 2008. Metal compounds for the treatment of parasitic diseases. J Inorg Biochem 102: 1839-1845.
40. Galarreta BC, Sifuentes R, Carrillo AK, Sanchez L, Amado M del R, Maruenda H 2008. The use of natural product scaffolds as leads in the search for trypanothione reductase inhibitors. Bioorg Med Chem 16: 6689-6695.
41. Galperin MY, Walker DR, Koonin EV 1998. Analogous enzymes: independent inventions in enzyme evolution. Genome Res 8: 779-790.
42. Guimarães AC, Otto TD, Alves-Ferreira M, Miranda AB, Degrave WM 2008. In silico reconstruction of the amino acid metabolic pathways of Trypanosoma cruzi. Genet Mol Res 7: 872-882.
43. Haemers T, Wiesner J, Gießmann D, Verbrugghen T, Hillaert U, Ortmann R, Jomaa H, Link A, Schlitzerd M, Van Calenbergha S 2008. Synthesis of b-and c-oxa isosteres of fosmidomycin and FR900098 as antimalarial candidates. Bio Med Chem 16: 3361-3371.
44. Hannaert V, Albert MA, Rigden DJ, da Silva Giotto MT, Thiemann O, Garratt RC, Van Roy J, Opperdoes FR, Michels PA 2003. Kinetic characterization, structure modelling studies and crystallization of Trypanosoma brucei enolase. Eur J Biochem 270: 3205-3213.
45. Heby O, Persson L, Rentala M 2007. Targeting the polyamine biosynthetic enzymes: a promising approach to therapy of African sleeping sickness, Chagas' disease and leishmaniasis. Amino Acids 33: 359-366.
46. Hudock MP, Sanz-Rodriguez CE, Song Y, Chan JM, Zhang Y, Odeh S, Kosztowski T, Leon-Rossell A, Concepcion JL, Yardley V, Croft SL, Urbina JA, Oldfield E 2006. Inhibition of Trypanosoma cruzi hexokinase by bisphosphonates. J Med Chem 49: 215-223.
47. Hurtado-Guerrrero R, Peña-Díaz J, Montalvetti A, Ruiz-Pérez LM, González-Pacanowska D 2002. Kinetic properties and inhibition of Trypanosoma cruzi 3-hydroxy-3-methylglutaryl CoA reductase. FEBS Letters 510: 141-144.
48. Igoillo-Esteve M, Maugeri D, Stern AL, Beluardi P, Cazzulo JJ 2007. The pentose phosphate pathway in Trypanosoma cruzi: a potential target for the chemotherapy of Chagas disease. An Acad Bras Cienc 79: 649-663.
49. Jiménez-Jiménez J, Ledesma A, Zaragoza P, González-Barroso MM, Rial E 2006. Fatty acid activation of the uncoupling proteins requires the presence of the central matrix loop from UCP1. Biochim Biophys Acta 1757: 1292-1296.
50. Juan SM, Cazzulo JJ, Segura EC 1976. The pyruvate kinase of Trypanosoma cruzi. Acta Physiol Lat Am 26: 424-426.
51. Jurado LA, Machín I, Urbina JA 1996. Trypanosoma cruzi phosphoenolpyruvate carboxykinase (ATP-dependent): transition metal ion requirement for activity and sulfhydryl group reactivity. Biochim Biophys Acta 1292: 188-196.
52. Kanehisa M, Goto S, Hattori M, Aoki-Kinoshita KF, Itoh M, Kawashima S, Katayama T, Araki M, Hirakawa M 2006. From genomics to chemical genomics: new developments in KEGG. Nucleic Acids Res 34: D354-D357.
53. Karp PD, Krummenacker M, Paley S, Wagg J 1999. Integrated pathway- genome databases and their role in drug discovery. Trends Biotechnol 17: 275-281.
54. Korn ED, Greenblatt CL 1963. Synthesis of alpha-linoleic acid by Leishmania enriettii. Science 142: 1301-1303.
55. Korn ED, Von Brand T, Tobie EJ 1969. The sterols of Trypanosoma cruzi and Crithidia fasciculata. Comp Biochem Physiol 30: 601-610.
56. Krauth-Siegel RL, Inhoff O 2003. Parasite-specific trypanothione reductase as a drug target molecule. Parasitol Res 90: S77-S85.
57. Lee SH, Stephens JL, Paul KS, Englund PT 2006. Fatty acid synthesis by elongases in trypanosomes. Cell 126: 691-699.
58. Liendo A, Visbal G, Piras MM, Piras R, Urbina JA 1999. Sterol composition and biosynthesis in Trypanosoma cruzi amastigotes. Mol Biochem Parasitol 104: 81-91.
59. Liñares GE, Ravaschino EL, Rodriguez JB 2006. Progresses in the field of drug design to combat tropical protozoan parasitic diseases. Curr Med Chem 13: 335-360.
60. Lorente SO, Jimenez CJ, Gros L, Yardley V, de Luca-Fradley K, Croft SL, Urbina J, Ruiz-Perez LM, Pacanowska DG, Gilbert IH 2005. Preparation of transition-state analogues of sterol 24-methyl transferase as potential anti-parasitics. Bioorg Med Chem 13: 5435-5453.
61. Magaraci F, Jimenez CJ, Rodrigues C, Rodrigues JC, Braga MV, Yardley V, de Luca-Fradley K, Croft SL, de Souza W, Ruiz-Perez LM, Urbina J, Gonzalez Pacanowska D, Gilbert IH 2003. Azasterols as inhibitors of sterol 24-methyltransferase in Leishmania species and Trypanosoma cruzi. J Med Chem 46: 4714-4727.
62. Marin-Neto JA, Rassi A Jr, Morillo CA, Avezum A, Connolly SJ, Sosa-Estani S, Rosas F, Yusuf S 2008. Rationale and design of a randomized placebo-controlled trial assessing the effects of etiologic treatment in Chagas' cardiomyopathy: the BENznidazole Evaluation for Interrupting Trypanosomiasis (BENEFIT). Am Heart J 156: 37-43.
63. Martyn DC, Jones DC, Fairlamb AH, Clardy J 2007. High-throughput screening affords novel and selective trypanothione reductase inhibitors with anti-trypanosomal activity. Bioorg Med Chem Lett 17: 1280-1283.
64. Maugeri DA, Cazzulo JJ 2004. The pentose phosphate pathway in Trypanosoma cruzi. FEMS Microbiol Lett 234: 117-123.
65. Maya JD, Cassels BK, Iturriaga-Vásquez P, Ferreira J, Faúndez M, Galanti N, Ferreira A, Morello A 2007. Mode of action of natural and synthetic drugs against Trypanosoma cruzi and their interaction with the mammalian host. Comp Biochem Physiol A Mol Integr Physiol 146: 601-620.
66. Michels PA, Hannaert V, Bringaud F 2000. Metabolic aspects of glycosomes in trypanosomatidae - new data and views. Parasitol Today 16: 482-489.
67. Mielniczki-Pereira AA, Chiavegatto CM, López JA, Colli W, Alves MJM, Gadelha FR 2007. Trypanosoma cruzi strains, Tulahuen 2 and Y, besides the difference in resistance to oxidative stress, display differential glucose-6-phosphate and 6-phosphogluconate dehydrogenases activities. Acta Tropica 101: 54-60.
68. Montalvetti A, Peña-Díaz J, Hurtado R, Ruiz-Pérez LM, González- Pacanowska D 2000. Characterization and regulation of Leishmania major 3-hydroxy-3-methylglutaryl-CoA reductase. Biochem J 349: 27-34.
69. Moyersoen J, Choe J, Fan E, Hol WG, Michels PA 2004. Biogenesis of peroxisomes and glycosomes: trypanosomatid glycosome assembly is a promising new drug target. FEMS Microbiol Rev 28: 603-643.
70. Olivares-Illana V, Pérez-Montfort R, López-Calahorra F, Costas M, Rodríguez-Romero A, Tuena de Gómez-Puyou M, Gómez Puyou A 2006. Structural differences in triosephosphate isomerase from different species and discovery of a multitrypanosomatid inhibitor. Biochemistry 45: 2556-2560.
71. Olivares-Illana V, Rodríguez-Romero A, Becker I, Berzunza M, García J, Pérez-Montfort R, Cabrera N, López-Calahorra F, Gómez-Puyou MT, Gómez-Puyou A 2007. Perturbation of the dimer interface of triosephosphate isomerase and its effect on Trypanosoma cruzi. PLoS Negl Trop Dis 1: e1.
72. Otto TD, Guimarães AC, Degrave WM, de Miranda AB 2008. AnEn- Pi: identification and annotation of analogous enzymes. BMC Bioinformatics 9: 544.
73. Paulino M, Iribarne F, Dubin M, Aguilera-Morales S, Tapia O, Stoppani AO 2005. The chemotherapy of Chagas' disease: an overview. Mini Rev Med Chem 5: 499-519.
74. Peña-Díaz J, Montalvetti A, Camacho A, Gallego C, Ruiz-Perez LM, Gonzalez-Pacanowska D 1997. A soluble 3-hydroxy-3-methylglutaryl- CoA reductase in the protozoan Trypanosoma cruzi. Biochem J 324: 619-626.
75. Pereira CA, Alonso GD, Paveto MC, Flawiá MM, Torres HN 1999. L-arginine uptake and L-phosphoarginine synthesis in Trypanosoma cruzi. J Eukaryot Microbiol 46: 566-570.
76. Pérez-Montfort R, Garza-Ramos G, Alcántara GH, Reyes-Vivas H, Gao XG, Maldonado E, de Gómez-Puyou MT, Gómez-Puyou A 1999. Derivatization of the interface cysteine of triosephosphate isomerase from Trypanosoma brucei and Trypanosoma cruzi as probe of the interrelationship between the catalytic sites and the dimer interface. Biochemistry 38: 4114-4120.
77. Perez-Pineiro R, Burgos A, Jones DC, Andrew LC, Rodriguez H, Suarez M, Fairlamb AH, Wishart DS 2009. Development of a novel virtual screening cascade protocol to identify potential trypanothione reductase inhibitors. J Med Chem 52: 1670-1680.
78. Pourshafie M, Morand S, Virion A, Rakotomanga M, Dupuy C, Loiseau PM 2004. Cloning of S-adenosyl-L-methionine: C-24-Delta-sterolmethyltransferase (ERG6) from Leishmania donovani and characterization of mRNAs in wild-type and amphotericin B-Resistant promastigotes. Antimicrob Agents Chemother 48: 2409-2414.
79. Racagni GE, Machado de Domenech EE 1983. Characterization of Trypanosoma cruzi hexokinase. Mol Biochem Parasitol 9: 181-188.
80. Reyes-Vivas H, Hernández-Alcantara G, López-Velazquez G, Cabrera N, Pérez-Montfort R, de Gómez-Puyou MT, Gómez-Puyou A 2001. Factors that control the reactivity of the interface cysteine of triosephosphate isomerase from Trypanosoma brucei and Trypanosoma cruzi. Biochemistry 40: 3134-3140.
81. Roberts CW, McLeod R, Rice DW, Ginger M, Chance ML, Goad LJ 2003. Fatty acid and sterol metabolism: potential antimicrobial targets in apicomplexan and trypanosomatid parasitic protozoa. Mol Biochem Parasitol 126: 129-142.
82. Rocha MO, Teixeira MM, Ribeiro AL 2007. An update on the management of Chagas cardiomyopathy. Expert Rev Anti Infect Ther 5: 727-743.
83. Rodríguez-Romero A, Hernández-Santoyo A, del Pozo Yauner L, Kornhauser A, Fernández-Velasco DA 2002. Structure and inactivation of triosephosphate isomerase from Entamoeba histolytica. J Mol Biol 322: 669-675.
84. Rogerson GW, Gutteridge WE 1980. Catabolic metabolism in Trypanosoma cruzi. Int J Parasitol 10: 131-135.
85. Sanz-Rodriguez CE, Concepcion JL, Pekerar S, Oldfield E, Urbina JA 2007. Bisphosphonates as inhibitors of Trypanosoma cruzi hexokinase: kinetic and metabolic studies. J Biol Chem 282: 12377-12387.
86. Schmunis GA 2007. Epidemiology of Chagas disease in non-endemic countries: the role of international migration. Mem Inst Oswaldo Cruz 102: 75-85.
87. Sgraja T, Smith TK, Hunter WN 2007. Structure, substrate recognition and reactivity of Leishmania major mevalonate kinase. BMC Struct Biol 7: 20.
88. Silber AM, Colli W, Ulrich H, Alves MJ, Pereira CA 2005. Amino acid metabolic routes in Trypanosoma cruzi: possible therapeutic targets against Chagas' disease. Curr Drug Targets Infect Disord 5: 53-64.
89. Silber AM, Rojas RL, Urias U, Colli W, Alves MJ 2006. Biochemical characterization of the glutamate transport in Trypanosoma cruzi. Int J Parasitol 36: 157-163.
90. Stephens JL, Lee SH, Paul KS, Englund PT 2007. Mitochondrial fatty acid synthesis in Trypanosoma brucei. J Biol Chem 282: 4427-4436.
91. Stern AL, Burgos E, Salmon L, Cazzulo JJ 2007. Ribose 5-phosphate isomerase type B from Trypanosoma cruzi: kinetic properties and site-directed mutagenesis reveal information about the reaction mechanism. Biochem J 401: 279-285.
92. Sylvester D, Krassner SM 1976. Proline metabolism in Trypanosoma cruzi epimastigotes. Comp Biochem Physiol B 55: 443-447.
93. Tarleton RL 2007. Immune system recognition of Trypanosoma cruzi. Curr Opin Immunol 19: 430-434.
94. Taylor MB, Gutteridge WE 1987. Trypanosoma cruzi: subcellular distribution of glycolytic and some related enzymes of epimastigotes. Expt Parasitol 63: 84-97.
95. Tetaud E, Bringaud F, Chabas S, Barrett MP, Baltz T 1994. Characterization of glucose transport and cloning of a hexose transporter gene in Trypanosoma cruzi. Proc Natl Acad Sci USA 91: 8278-8282.
96. Tielens AG, Van Hellemond JJ 1998. Differences in energy metabolism between trypanosomatidae. Parasitol Today 14: 265-272.
97. Trapani S, Linss J, Goldenberg S, Fischer H, Craievich AF, Oliva G 2001. Crystal structure of the dimeric phosphoenolpyruvate carboxykinase (PEPCK) from Trypanosoma cruzi at 2 A resolution. J Mol Biol 313: 1059-1072.
98. Urbina JA 1997. Lipid biosynthesis pathways as chemotherapeutic targets in kinetoplastid parasites. Parasitology 114: S91-S99.
99. Urbina JA, Crespo A 1984. Regulation of energy metabolism in Trypanosoma (Schizotrypanum) cruzi epimastigotes. I. Hexokinase and phosphofructokinase. Mol Biochem Parasitol 11: 225-239.
100. Urbina JA, Docampo R 2003. Specific chemotherapy of Chagas disease: controversies and advances. Trends Parasitol 19: 495-501.
101. Urbina JA, Machin I, Jurado L 1993. The limitations of paradigms: studies on the intermediary metabolism of Trypanosoma cruzi. Biol Res 26: 81-88.
102. Urbina JA, Osorno CE, Rojas A 1990. Inhibition of phosphoenolpyruvate carboxykinase from Trypanosoma (Schizotrypanum) cruzi epimastigotes by 3-mercaptopicolinic acid: in vitro and in vivo studies. Arch Biochem Biophys 282: 91-99.
103. van Hellemond JJ, Opperdoes FR, Tielens AG 2005. The extraordinary mitochondrion and unusual citric acid cycle in Trypanosoma brucei. Biochem Soc Trans 33: 967-971.
104. van Hellemond JJ, Tielens AG 2006. Adaptations in the lipid metabolism of the protozoan parasite Trypanosoma brucei. FEBS Lett 580: 5552-5558.
105. van Weelden SW, van Hellemond JJ, Opperdoes FR, Tielens AG 2005. New functions for parts of the Krebs cycle in procyclic Trypanosoma brucei, a cycle not operating as a cycle. J Biol Chem 280: 12451-12460.
106. Von Brand T, Agosin M 1955. The utilization of Krebs cycle intermediates by the culture forms of Trypanosoma cruzi and Leishmania tropica. J Infect Dis 97: 274-279.
107. Wiemer EA, IJlst L, van Roy J, Wanders RJ, Opperdoes FR 1996. Identification of 2-enoyl coenzyme A hydratase and NADP(+)- dependent 3-hydroxyacyl-CoA dehydrogenase activity in glycosomes of procyclic Trypanosoma brucei. Mol Biochem Parasitol 82: 107-111.
108. Wiesner J, Jomaa H 2007. Isoprenoid biosynthesis of the apicoplast as drug target. Curr Drug Targets 8: 3-13.